scholarly journals How Researchers Define Vulnerable Populations in HIV/AIDS Clinical Trials

2010 ◽  
Vol 14 (6) ◽  
pp. 1313-1319 ◽  
Author(s):  
Sohini Sengupta ◽  
Bernard Lo ◽  
Ronald P. Strauss ◽  
Joseph Eron ◽  
Allen L. Gifford
Keyword(s):  
Clinical Trials ◽  
Vulnerable Populations ◽  
Aids Clinical Trials ◽  
Hiv Aids

scholarly journals Community-Researcher Partnerships at NIAID HIV/AIDS Clinical Trials Sites: Insights for Evaluation and Enhancement

2012 ◽  
Vol 6 (3) ◽  
pp. 311-320 ◽  
Author(s):  
Jonathan M. Kagan ◽  
Scott R. Rosas ◽  
Rona L. Siskind ◽  
Russell D. Campbell ◽  
Daniel Gondwe ◽  
...  
Keyword(s):  
Clinical Trials ◽  
Aids Clinical Trials ◽  
Hiv Aids

Use of Complementary Medicine by Adult Patients Participating in HIV/AIDS Clinical Trials

2000 ◽  
Vol 6 (5) ◽  
pp. 415-422 ◽  
Author(s):  
Andrew Sparber ◽  
Jacqueline C. Wootton ◽  
Larry Bauer ◽  
Gregory Curt ◽  
David Eisenberg ◽  
...  
Keyword(s):  
Clinical Trials ◽  
Complementary Medicine ◽  
Adult Patients ◽  
Aids Clinical Trials ◽  
Hiv Aids

Implementing Community Involvement in National Institutes of Health (NIH) HIV/AIDS Clinical Trials Networks

2014 ◽  
Vol 30 (S1) ◽  
pp. A107-A107
Author(s):  
Rona Siskind ◽  
Neetha S. Morar ◽  
Russell D. Campbell ◽  
Jeffrey Schouten
Keyword(s):  
Clinical Trials ◽  
Community Involvement ◽  
National Institutes Of Health ◽  
Aids Clinical Trials ◽  
Hiv Aids

scholarly journals Engaging Transgender People in NIH-Funded HIV/AIDS Clinical Trials Research

2016 ◽  
Vol 72 ◽  
pp. S243-S247 ◽  
Author(s):  
Rona L. Siskind ◽  
Michele Andrasik ◽  
Shelly T. Karuna ◽  
Gail B. Broder ◽  
Clare Collins ◽  
...  
Keyword(s):  
Clinical Trials ◽  
Transgender People ◽  
Aids Clinical Trials ◽  
Hiv Aids

scholarly journals Evaluating protocol lifecycle time intervals in HIV/AIDS clinical trials

2014 ◽  
Vol 11 (5) ◽  
pp. 553-559 ◽  
Author(s):  
Scott R Rosas ◽  
Jeffrey T Schouten ◽  
Dennis Dixon ◽  
Suresh Varghese ◽  
Marie T Cope ◽  
...  
Keyword(s):  
Clinical Trials ◽  
Time Intervals ◽  
Aids Clinical Trials ◽  
Hiv Aids

Compensation for Research-Related Injury in NIH-Sponsored HIV/AIDS Clinical Trials in Africa

2013 ◽  
Vol 8 (1) ◽  
pp. 45-54 ◽  
Author(s):  
Nicole Mamotte ◽  
Douglas Wassenaar ◽  
Nivedhna Singh
Keyword(s):  
Clinical Trials ◽  
Aids Clinical Trials ◽  
Hiv Aids

The Role of Social Work in HIV/AIDS Clinical Trials

1999 ◽  
Vol 29 (1) ◽  
pp. 35-56 ◽  
Author(s):  
Judith K. Williams ◽  
Fred Boykin
Keyword(s):  
Clinical Trials ◽  
Social Work ◽  
Aids Clinical Trials ◽  
Hiv Aids

scholarly journals HIV/AIDS Clinical Trials: A Statistical Review

2006 ◽  
Vol 5 (2) ◽  
pp. 71-85
Author(s):  
Annie Sumithri Soans ◽  
Nagaraja Rao Chillale ◽  
T. Srivenkataramana
Keyword(s):  
Infectious Disease ◽  
Clinical Trials ◽  
Bayesian Analysis ◽  
Incomplete Data ◽  
Meta Analysis ◽  
Economic Stability ◽  
Statistical Review ◽  
The World ◽  
Aids Clinical Trials ◽  
Hiv Aids

The HIV pandemic has grown to become one of the greatest infectious disease threats, to human health and to socio-economic stability that the world has ever encountered.It is imperative that the epidemic is controlled as rapidly as possible through prevention of new infections.Carefully conducted clinical trials are the fastest and safest way to find treatments that work in people to improve health.When the objectives or the endpoints of clinical trials for HIV/AIDS are carefully defined then Statistics will be very useful not only in designing the trial and formulating hypothesis but also in providing guidance in the analysis of the data on completion of the trial and to enhance the credibility of the results.This article mainly reviews the analysis of HIV/AIDS clinical trials.Concepts such as meta-analysis,analysis in the case of incomplete data and Bayesian analysis in the context of HIV/AIDS have also been covered.

The ACT2 Program and Eliminating Racial and Ethnic Disparities in HIV and AIDS Clinical Trials: A Case Study in Health and Risk Messaging

2017 ◽  
Author(s):  
Marya Gwadz ◽  
Amanda S. Ritchie
Keyword(s):  
Clinical Trials ◽  
Medical Research ◽  
The United States ◽  
Hiv And Aids ◽  
People Of Color ◽  
Color Experience ◽  
American Black ◽  
Aids Clinical Trials ◽  
Living With Hiv ◽  
Hiv Aids

It is well documented that African American/Black and Hispanic individuals are underrepresented in biomedical research in the United States (U.S.), and leaders in the field have called for the proportional representation of varied populations in biomedical studies as a matter of social justice, economics, and science. Yet achieving appropriate representation is particularly challenging for health conditions that are highly stigmatized such as HIV/AIDS. African American/Black, and Hispanic individuals, referred to here as “people of color,” are greatly overrepresented among the 1.2 million persons living with HIV/AIDS in the United States. Despite this, people of color are substantially underrepresented in AIDS clinical trials. AIDS clinical trials are research studies to evaluate the safety and effectiveness of promising new treatments for HIV and AIDS and for the complications of HIV/AIDS, among human volunteers. As such, AIDS clinical trials are critical to the development of new medications and treatment regimens. The underrepresentation of people of color in AIDS clinical trials has been criticized on a number of levels. Of primary concern, underrepresentation may limit the generalizability of research findings to the populations most affected by HIV/AIDS. This has led to serious concerns about the precision of estimates of clinical efficacy and adverse effects of many treatments for HIV/AIDS among these populations. The reasons for the underrepresentation of people of color are complex and multifaceted. First, people of color experience serious emotional and attitudinal barriers to AIDS clinical trials such as fear and distrust of medical research. These experiences of fear and distrust are grounded largely in the well-known history of abuse of individuals of color by medical research institutions, and are complicated by current experiences of exclusion and discrimination in health care settings and the larger society, often referred to as structural racism or structural violence. In addition, people of color experience barriers to AIDS clinical trials at the level of social networks, such as social norms that do not support engagement in medical research and preferences for alternative therapies. People of color living with HIV/AIDS experience a number of structural barriers to clinical trials, such as difficulty accessing and navigating the trials system, which is often unfamiliar and daunting. Further, most health care providers are not well positioned to help people of color overcome these serious barriers to AIDS clinical trials in the context of a short medical appointment, and therefore are less likely to refer them to trials compared to their White peers. Last, some studies suggest that the trials’ inclusion and exclusion criteria exclude a greater proportion of people of color than White participants. Social/behavioral interventions that directly address the historical and contextual factors underlying the underrepresentation of people of color in AIDS clinical trials, build motivation and capability to access trials, and offer repeated access to screening for trials, hold promise for eliminating this racial/ethnic disparity. Further, modifications to study inclusion criteria will be needed to increase the proportion of people of color who enroll in AIDS clinical trials.

Sign in / Sign up

Export Citation Format

Share Document